secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001493152-24-018426
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q1 2024 net loss $5.4M, cash $38.4M; clinical trials advance
---------------------------------------------------------------------------

- Net loss $5.4M ($0.51/share) vs $3.9M ($0.36/share) in Q1 2023; R&D expense $4.3M vs $2.6M.
- Cash, cash equivalents & marketable securities $38.4M at Mar 31, 2024, down from $41.3M at Dec 31, 2023.
- Phase 1 trials for LP-184 and LP-284 continue with no dose-limiting toxicities; LP-184 enrollment to complete summer 2024.
- Regulatory allowance granted to begin Phase 2 Harmonic trial in Japan and Taiwan for LP-300 in never-smoker NSCLC.
- ADC program advanced: novel cryptophycin-based ADC shows picomolar potency and 80% cancer cell kill rate in preclinical studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315224018426/0001493152-24-018426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315224018426/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer